Australian Public Assessment Reports (AusPAR)

Australian Public Assessment Report for Ixekizumab

Australian Public Assessment Report for Daclizumab

Australian Public Assessment Report for Deoxycholic acid

Australian Public Assessment Report for Paritaprevir / Ritonavir / Ombitasvir and Dasabuvir (as Sodium Salt)

Australian Public Assessment Report for Paritaprevir / Ritonavir / Ombitasvir and Dasabuvir (as sodium salt) and Ribavirin

Australian Public Assessment Report for Nine trace elements including chromic chloride

Australian Public Assessment Report for Adalimumab

Australian Public Assessment Report for Brivaracetam

Australian Public Assessment Report for mepolizumab (rch)

Forxiga (dapagliflozin) was approved as an adjunct to diet and exercise in patients with type 2 diabetes mellitus for whom metformin is otherwise indicated but not tolerated. It was also approved as a combination therapy to be used with other drugs to improve glycaemic control.

Australian Public Assessment Report for Ipilimumab (rch)

Australian Public Assessment Report for Rituximab

Australian Public Assessment Report for Gadobutrol

Australian Public Assessment Report for Insulin glargine (rbe)

Australian Public Assessment Report for Ivacaftor

Australian Public Assessment Report for Ivacaftor

Australian Public Assessment Report for Human Papillomavirus 9 valent vaccine

Australian Public Assessment Report for Tiotropium bromide

AusPAR: Buprenorphine

Australian Public Assessment Report for Levonorgestrel / ethinyloestradiol

Australian Public Assessment Report for Tiotropium bromide

Australian Public Assessment Report for Secukinumab

Australian Assessment Report for Tenofovir disoproxil fumarate / Emtricitabine

Australian Assessment Report for Selexipag